Foundation Medicine, Inc., a genomics company committed to transforming cancer care, today announced that it has expanded its immunohistochemistry (IHC) test offerings to include MET IHC testing using ...

The National Health Insurance Administration (NHIA) is to expand National Health Insurance (NHI) coverage to include two ...

IMNN-001 is the first and only immunotherapy to show meaningful overall survival benefit in a Phase 2 trial in women with advanced ovarian cancer Data from Phase 2 OVATION 2 Study are encouraging, ...

Initial results from the LANCE trial show comparable rates of resection with minimally invasive surgery and laparotomy in advanced epithelial ovarian cancer.

Data from the NERO study investigating Zejula in mesothelioma was presented at the American Association of Cancer Research Meeting 2025.

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, ...

Zejula was approved in 2017 for the second-line maintenance indication in ovarian, fallopian tube, or primary peritoneal cancer, becoming the first drug in the PARP class that could be used in all ...

The peritoneal cavity of advanced ovarian cancer patients contains the primary tumor environment and is an attractive target for a regional approach to immune modulation. IMUNON is a clinical ...

Title : Claudin18.2-specific CAR T cells (Satri-cel) versus treatment of physician's choice (TPC) for previously treated ...